Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBITDA: 2017-2025

Historic EBITDA for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to -$36.7 million.

  • Dianthus Therapeutics' EBITDA fell 50.07% to -$36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.9 million, marking a year-over-year decrease of 91.04%. This contributed to the annual value of -$84.9 million for FY2024, which is 95.88% down from last year.
  • Per Dianthus Therapeutics' latest filing, its EBITDA stood at -$36.7 million for Q3 2025, which was down 15.41% from -$31.8 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' EBITDA ranged from a high of -$7.0 million in Q1 2023 and a low of -$36.7 million during Q3 2025.
  • Moreover, its 3-year median value for EBITDA was -$17.6 million (2024), whereas its average is -$20.6 million.
  • Data for Dianthus Therapeutics' EBITDA shows a maximum YoY tumbled of 176.02% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' EBITDA stood at -$10.1 million in 2022, then fell by 3.80% to -$10.5 million in 2023, then plummeted by 176.02% to -$29.0 million in 2024, then tumbled by 50.07% to -$36.7 million in 2025.
  • Its last three reported values are -$36.7 million in Q3 2025, -$31.8 million for Q2 2025, and -$29.3 million during Q1 2025.